Short answer
Annexon, Inc. (ANNX) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 excluded from incorporation by reference into future SEC filings.
Annexon, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 excluded from incorporation by reference into future SEC filings
- Section provides no earnings figures or operating results; investor-relevant details require review of Exhibit 99.1
Item 8.01 · Other Events
- Annexon expanded vonaprument’s Phase 3 geographic atrophy program with a Month 24 dual primary endpoint
- Month 24 endpoint complements the existing Month 15 primary endpoint
- Open-label extension study launch extends patient follow-up and may provide additional long-term efficacy and safety data
- Details and management commentary are provided in Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.2
- Q2 net loss $55.3M, or $0.28 per share, versus $49.2M and $0.34 in Q2 2025
- Cash, equivalents and short-term investments $209.2M at June 30, with runway expected into 2028
- Oxford Finance credit facility up to $200M, including $50M initially drawn, strengthening near-term funding
- Tanruprubart BLA submission expected in Q4 2026 following positive FORWARD GBS outcomes
- Vonaprument Month 15 ARCHER II endpoint remains on track for Q4 2026, with Month 24 completion expected Q3 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Annexon, Inc. 8-K filings
Get the next ANNX 8-K as it lands
Follow ANNX for push alerts, or ask the research agent what this filing means.